Amylyx co-CEOs Justin Klee (L) and Josh Cohen
October 17, 2024 03:22 PM EDT
R&D

Amy­lyx presents full Phase 2 da­ta for with­drawn ALS drug in an­oth­er rare ge­net­ic dis­ease

Max Gelman

Senior Editor

Amy­lyx is try­ing to move for­ward with its ef­fort to turn its for­mer ALS drug in­to a treat­ment for oth­er con­di­tions, and da­ta re­leased Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times